Why the study?
Does early biomarker-guided detection and prophylactic treatment with ACE inhibitors prevent LVEF reduction and cardiac events in cancer patients on chemotherapy?
Population
Cancer patients on chemotherapy at risk of cardiotoxicity
Comparison
Measurement of cardio-specific biomarkers for… vs Current standard for monitoring cardiac function
Design
Review
Authors
Loading...
Biomarker monitoring may enable earlier prophylaxis before functional decline; leaves open optimal thresholds for routine practice.
Does early biomarker-guided detection and prophylactic treatment with ACE inhibitors prevent LVEF reduction and cardiac events in cancer patients on chemotherapy?
Biomarker-guided early detection of cardiotoxicity and prompt initiation of ACE inhibitors may prevent irreversible left ventricular dysfunction in cancer patients undergoing chemotherapy.
Bacchiani et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: